Barclays rated Overweight COVIDIEN LTD. COMMON SHARES (NYSE: COV) on 05/08/2012, when the stock price was $54.40. Since then, COVIDIEN LTD. COMMON SHARES has gained 96.16% as of 01/26/2016's recent price of $106.71.
If you would have followed this Barclays's recommendation on COV, you would have gained 96.15% of your investment in 1358 days.

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines, including Surgical Devices, Energy-Based Devices, Respiratory and Monitoring Solutions, Patient Care and Safety Products, Imaging Solutions, Pharmaceutical Products, Medical Supplies and Retail Products.

Barclays

Marked as spam